ICOS: Advanced Dyslipidemia Management for CV Risk Reduction
ICOS: Advanced Dyslipidemia Management for CV Risk Reduction
25% risk reduction of 5- Point MACE in REDUCE-IT trial1,2
Composite first occurrence of 5-point MACE (primary endpoint)
25% RRR NNT=21
ARR=4.8% P=0.00000001
At Year 5 since randomization, 1430 patients remained in the Icospent Ethyl arm vs 1358 patients in the placebo arm. 5- point MACE primary composite endpoint was defined as Nonfatal MI, Nonfatal Stroke, CV Death, Coronary Revasucularization, or Unstable Angina Requiring Hospitalization. Patients in the Placebo + Statin arm had a cumulative 28.3% event rate, which is consistent for this high-risk population3
To explore how ICOS can assist your CV patients and connect you with a medical rep, please tick the box below:
GGI-CO-A1-AQS-300040480-ELC-H24-1446
REDUCE-IT: Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial; TG: Triglycerides; CVD: Cardiovascular Diseases; ARR: Absolute Risk Reduction; MACE: Major Adverse Cardiovascular Event; NNT: Number Needed to treat; RRR: Relative Risk Reduction
References:
1.
Prescribing information of ICOS,generated & latest modified on June 2023.
2.
Bhatt DL, Steg PG, Miller M, et al; on behalf of the REDUCE-IT Investigators. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791-2802.
3.
Journal of Cardiology 70 (2017) 537–544.
*Prescribing information of ICOS, generated & latest modified on June 2023.
